Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -2.78% | 151.88 | 0.7% | $1185.40m | |
| PFE | Pfizer Inc. | -1.35% | 33.93 | 0.9% | $1169.30m | |
| MRK | Merck & Co., Inc. | -1.88% | 71.93 | 0.7% | $848.30m | |
| BMY | Bristol-Myers Squibb Co. | -2.91% | 58.99 | 1.0% | $788.61m | |
| ABBV | AbbVie, Inc. | -1.46% | 105.15 | 1.9% | $735.20m | |
| LLY | Eli Lilly & Co. | -1.34% | 199.29 | 1.1% | $638.61m | |
| AZN | AstraZeneca Plc | -1.13% | 46.63 | 1.2% | $491.58m | |
| GSK | GlaxoSmithKline Plc | -0.76% | 33.98 | 0.2% | $281.50m | |
| NVS | Novartis AG | -1.67% | 82.78 | 0.2% | $164.35m | |
| SNY | Sanofi | -0.01% | 45.46 | 0.2% | $156.14m | |
| VTRS | Viatris, Inc. | -3.47% | 13.40 | 0.0% | $146.57m | |
| VERU | Veru, Inc. | -11.41% | 11.65 | 0.0% | $96.90m | |
| NVO | Novo Nordisk A/S | -3.74% | 68.79 | 0.1% | $83.95m | |
| KALV | KalVista Pharmaceuticals, Inc. | -3.48% | 31.07 | 0.4% | $80.83m | |
| RPRX | Royalty Pharma Plc | -4.25% | 41.72 | 0.2% | $79.35m |
Company Profile
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.